One of the largest global medical technology companies in the world, Becton-Dickinson (BD), is no stranger to acting fast during a crisis, and the COVID-19 pandemic is no different.
In tandem with manufacturing personal protective equipment (PPE) and ventilators, the need for improvements in COVID-19 testing remains critical.
Since the beginning of this pandemic, BD has been working hard to create an efficient COVID-19 test capacity in the United States. Specifically, over the last few months, BD has collaborated with additional organizations to help speed up the availability of testing results on their BD MAX™ System. The BD MAX™ System is a molecular diagnostic platform that is currently used in thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period.
BD’s collaboration landed them their first Emergency Use Authorization (EAU) by the Food and Drug Administration (FDA) for additional COVID-19 diagnostic testing that can return results in two to three hours. But, as COVID-19 continues to sweep the nation, testing adjustments had to be made. Just last month, BD was granted a second EAU by the FDA for an additional molecular diagnostic test for COVID-19 that can return results in two to three hours on their The BD MAX™ System. This test is in addition to the first EAU but this time is based on the Complement-dependent Cytotoxicity assay design.
In a recent press release, president of Integrated Diagnostic Solutions for BD, Dave Hickey, shared, “The new BD COVID-19 test for the BD MAX™ System will help increase availability of these much-needed tests around the world. We continue to work towards a full portfolio of testing options to give health care workers choice and access to the right test for the right situation.”
We thank BD and the work they have done in the fight against this pandemic.
Have a COVID-19 Hero you would like to nominate? Please reach out to Alexa Rice with details.